4-Fluoro-2-nitroanisole | CAS:445-83-0

We serve 4-Fluoro-2-nitroanisole CAS:445-83-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
 4-Fluoro-2-nitroanisole

Chemical Name:    4-Fluoro-2-nitroanisole
CAS.NO: 445-83-0
Synonyms:4-fluoro-1-methoxy-2-nitrobenzene;
4-Fluoro-2-Nitroanisole;
Molecular Formula:C7H6FNO3
Molecular Weight: 171.12600
 
Physical and Chemical Properties:
Density: 1.321 g/cm3
Melting point:62-64 °C(lit.)
Boiling point: 272.4ºC at 760 mmHg
Flash point:118.5ºC
Index of Refraction:1.521
 
Specification:
Appearance: powder
Purity:≥99.0%
 
Packing:25kg/drum
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:   used in thePharmaceutical intermediate



Contact us for information like 4-Fluoro-2-nitroanisole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Fluoro-2-Nitroanisole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Fluoro-2-nitroanisole Use and application,4-fluoro-1-methoxy-2-nitrobenzene technical grade,usp/ep/jp grade.


Related News: Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.4-Fluorobutanol manufacturer Singapore, Australia, New Zealand, and the United States have banned all foreign nationals traveling from China from entering the country.2,5-Difluoro-4-iodopyridine supplier Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.3-Bromo-2-fluoropyridine vendor A key publication in a preclinical model demonstrated rigosertib’s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: “A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.” Cell 165, 643).The US National Institutes of Health is working on a preventative vaccine, but it will likely take a few months until the first phase of clinical trials get underway, and more than a year until a vaccine might be available, according to experts.